Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation

Kidney transplantation is the best treatment for patients with end-stage renal disease (ESRD) because of a significant survival benefit conferred compared to patients who remain on haemodialysis.1 Although the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with ESRD has significantly declined over time, it remains at least 4-times higher than in the general population.2,3 Chronic HCV or HBV infection can result in chronic liver disease, cirrhosis, and hepatocellular carcinoma4 –6 and increase the risk of chronic kidney disease (CKD).

Source: Journal of Hepatology - March 13, 2019 Category: Gastroenterology Authors: H élène Fontaine, Laurent Alric, Julien Labreuche, Benjamin Legendre, Alexandre Louvet, Corinne Antoine, Christophe M. Legendre, Marc Hazzan, Nassim Kamar, Sebastien Dharancy, Stanislas Pol, Alain Duhamel, Philippe Mathurin Tags: Research Article Source Type: research